BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Sees Hot Market Potential for NanoAb Pipeline
- The global dermatology pharmaceutics market is booming, with increased public awareness and large unmet needs
- BiondVax competitor MoonLake Immunotherapeutics share price jumped 128% after positive findings from a Phase 2 trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, a painful long-term dermatological condition
- BiondVax’s NanoAbs address psoriasis and a broad range of other diseases, and with a potentially better safety profile based on administration directly into lesions, rather than MoonLake’s systemic-administration
The global dermatology pharmaceutics market was valued just over $20 billion in 2022 and is expected to surge to nearly $40 billion by 2030, growing at a CAGR of 8.91% during the forecast period (https://nnw.fm/JrIoe ). Dermatology uses pharmaceuticals to control and treat numerous conditions that affect the skin, hair, nails, and more.
BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company focused on developing, manufacturing, and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is developing a pipeline of unique nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments with large growing markets – including dermatological conditions such as psoriasis.
MoonLake Immunotherapeutics (NASDAQ: MLTX), a BiondVax competitor, recently reported positive results from its Phase 2 clinical trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”), a painful long-term dermatological condition characterized by the occurrence of inflamed and swollen lumps that significantly limit many everyday activities. The MIRA trial (M1095-HS-201) recruited 234 patients and is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (“HiSCR”) 75 as its primary endpoint, a higher measure of clinical response versus the HiSCR50 measure, which is commonly used in other clinical trials – representing a landmark milestone in the treatment of HS. The result, according to SeekingAlpha, was a stock jump of 128% (https://nnw.fm/sAEKm ).
The biological target of MoonLake’s Nanobody is the human immune system cytokine IL-17. IL-17 is implicated in several diseases. It’s important to remember that MoonLake’s MIRA trial does not pertain to psoriasis but rather to the indication of the orphan disease HS whose market is much smaller. BiondVax is initially targeting IL-17 for treatment of psoriasis, where the market size for therapeutics is expected to reach $44 Billion by 2031. The company’s plan for the IL-17 nanobody also includes addressing diseases like HS, psoriatic arthritis, and other large markets. BiondVax also intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patients targeted in a previous MoonLake’s trial.
In addition, unlike MoonLake’s nanobody formulation, BiondVax’s NanoAbs do not require the conjugation of two antibodies with a linker and do not require albumin attachment, making BiondVax’s therapy easier and cheaper to produce. While MoonLake’s nanobody exhibited a favorable safety profile, BiondVax’s therapies are designed to be injected directly into psoriatic lesions, and therefor are expected to provide an even better safety profile than systemic therapies like MoonLake’s.
MoonLake’s success proves how hungry the market has become for nanobody therapies that target IL-17. Moonlake’s market value was $1.8 billion at the end of the Phase 2 trial, a clear indicator that BiondVax has massive potential to grow exponentially.
BiondVax works in collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, and research teams have verified a strong affinity by the NanoAbs to their biological target molecules and exceptionally high thermostability. These NanoAbs have also demonstrated strong neutralization by several candidates – which BiondVax will continue to explore as it develops its pipeline for various underserved indications.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The global dermatology pharmaceutics market is booming, with increased public awareness and large unmet needs
- BiondVax competitor MoonLake Immunotherapeutics share price jumped 128% after positive findings from a Phase 2 trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, a painful long-term dermatological condition
- BiondVax’s NanoAbs address psoriasis and a broad range of other diseases, and with a potentially better safety profile based on administration directly into lesions, rather than MoonLake’s systemic-administration
The global dermatology pharmaceutics market was valued just over $20 billion in 2022 and is expected to surge to nearly $40 billion by 2030, growing at a CAGR of 8.91% during the forecast period (https://nnw.fm/JrIoe ). Dermatology uses pharmaceuticals to control and treat numerous conditions that affect the skin, hair, nails, and more.
BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company focused on developing, manufacturing, and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is developing a pipeline of unique nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments with large growing markets – including dermatological conditions such as psoriasis.
MoonLake Immunotherapeutics (NASDAQ: MLTX), a BiondVax competitor, recently reported positive results from its Phase 2 clinical trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”), a painful long-term dermatological condition characterized by the occurrence of inflamed and swollen lumps that significantly limit many everyday activities. The MIRA trial (M1095-HS-201) recruited 234 patients and is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (“HiSCR”) 75 as its primary endpoint, a higher measure of clinical response versus the HiSCR50 measure, which is commonly used in other clinical trials – representing a landmark milestone in the treatment of HS. The result, according to SeekingAlpha, was a stock jump of 128% (https://nnw.fm/sAEKm ).
The biological target of MoonLake’s Nanobody is the human immune system cytokine IL-17. IL-17 is implicated in several diseases. It’s important to remember that MoonLake’s MIRA trial does not pertain to psoriasis but rather to the indication of the orphan disease HS whose market is much smaller. BiondVax is initially targeting IL-17 for treatment of psoriasis, where the market size for therapeutics is expected to reach $44 Billion by 2031. The company’s plan for the IL-17 nanobody also includes addressing diseases like HS, psoriatic arthritis, and other large markets. BiondVax also intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patients targeted in a previous MoonLake’s trial.
In addition, unlike MoonLake’s nanobody formulation, BiondVax’s NanoAbs do not require the conjugation of two antibodies with a linker and do not require albumin attachment, making BiondVax’s therapy easier and cheaper to produce. While MoonLake’s nanobody exhibited a favorable safety profile, BiondVax’s therapies are designed to be injected directly into psoriatic lesions, and therefor are expected to provide an even better safety profile than systemic therapies like MoonLake’s.
MoonLake’s success proves how hungry the market has become for nanobody therapies that target IL-17. Moonlake’s market value was $1.8 billion at the end of the Phase 2 trial, a clear indicator that BiondVax has massive potential to grow exponentially.
BiondVax works in collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, and research teams have verified a strong affinity by the NanoAbs to their biological target molecules and exceptionally high thermostability. These NanoAbs have also demonstrated strong neutralization by several candidates – which BiondVax will continue to explore as it develops its pipeline for various underserved indications.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
